AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31254273
Drug: Plazomicin-based combination
RxNorm normalized name: plazomicin
DrugBank: Plazomicin (DB12615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plazomicin-based combination therapy (with adjunctive tigecycline or meropenem)
Trial: 31254273
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Colistin-based combination therapy)
Trial: 31254392
Drug: Glecaprevir/Pibrentasvir (G/P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/Pibrentasvir (G/P) 300 mg/120 mg once daily for 8-16 weeks
Trial: 31254392
Drug: Glecaprevir/Pibrentasvir (G/P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/Pibrentasvir (G/P)
Trial: 31255290
Drug: Closed-loop vasopressor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop vasopressor (CLV) control with norepinephrine infusion
Trial: 31256026
Drug: Secure prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secure prescription pads for zolpidem
Trial: 31256030
Drug: Multimodal imaging
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimodal imaging and image review by an ophthalmic grader
Trial: 31256774
Drug: Post-operative multimodal
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative multimodal analgesic regimen
Trial: 31257724
Drug: Obinutuzumab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obinutuzumab (1000 mg) plus IVIG
Trial: 31259266
Drug: No anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulant
Trial: 31260835
Drug: GSK2879552 (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2879552 (0.25 mg-3 mg once daily and 3-mg or 4-mg intermittent dosing)
Trial: 31261514
Drug: Apatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib plus docetaxel (docetaxel 75 mg/m² i.v. on day 1 plus oral apatinib 250 mg/day)
Trial: 31262585
Drug: Hecolin® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hecolin® vaccine (3 doses at day 0, month 1, month 6)
Trial: 31262783
Drug: CD19-specific chimeric
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-specific chimeric antigen receptor (CAR) T cells administered following high-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) on days +2 and +3.
Trial: 31263960
Drug: Daily physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physical activity assessed in steps/day using an arm-worn accelerometer (SenseWear) over 1 week.
Trial: 31263960
Drug: 6-minute walking
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-minute walking distance (6MWD) as an independent predictor of daily steps.
Trial: 31263960
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of daily physical activity with hemodynamics and other outcomes.
Trial: 31267239
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of beta-blockers, renin-angiotensin system inhibitors, and mineralocorticoid receptor antagonists
Trial: 31267365
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training exercises in more simple forms (e.g. elastic bands, body weight)
Trial: 31267801
Drug: Adalimumab with
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab with ≥12 mg/week methotrexate
Trial: 31269208
Drug: Raltegravir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir (400 mg twice daily) / Etravirine (200 mg twice daily)
Trial: 31270103
Drug: DARA-MD 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DARA-MD 1200 mg
Trial: 31270103
Drug: DARA-MD 1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DARA-MD 1800 mg
Trial: 31271463
Drug: Maternal tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Maternal tenofovir treatment during the third trimester
Trial: 31271463
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no tenofovir treatment)
Trial: 31273088
Drug: Eltrombopag, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag, an oral thrombopoietin-mimetic, dosage and duration not specified
Trial: 31274114
Drug: Biological markers
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological markers for drug use
Trial: 31274114
Drug: Biological markers
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological markers for sexual HIV transmission risk
Trial: 31274114
Drug: Biological markers
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological markers for PrEP adherence
Trial: 31276005
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for ATR
Trial: 31276163
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg) IV every 2 weeks
Trial: 31277699
Drug: MK-2206 (AKT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-2206 (AKT inhibitor)
Trial: 31277722
Drug: Sedatives only
RxNorm normalized name: Sed-Max
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedatives only
Trial: 31277722
Drug: Sedatives plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedatives plus opioids
Trial: 31279304
Drug: Ibrutinib (560
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (560 mg/day) until disease progression or unacceptable toxicity
Trial: 31279304
Drug: Ibrutinib (560
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (560 mg/day)
Trial: 31279564
Drug: MenACWY-CRM (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM (4 doses during infancy)
Trial: 31279564
Drug: MenACWY-CRM (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM (2 doses at 12/13 and 15 months or 1 dose at 18 months)
Trial: 31279564
Drug: MenACWY-CRM booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM booster dose at 60 months
Trial: 31279871
Drug: Vedolizumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab (300 mg intravenously at weeks 0, 2, and 6, then every 8 weeks thereafter for 26 weeks)
Trial: 31280362
Drug: Erdafitinib (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdafitinib (doses ranging from 0.5 to 12 mg, with a highest therapeutic dose of 9 mg daily)
Trial: 31284072
Drug: Patent Blue
RxNorm normalized name: Patent Blue
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patent Blue injection into different parts of the pancreas
Trial: 31284680
Drug: Aerosol with
RxNorm normalized name: AEROSOL WITH ADAPTER (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol with active heated humidification at 10 L/min
Trial: 31284680
Drug: Aerosol with
RxNorm normalized name: AEROSOL WITH ADAPTER (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol with active heated humidification at 30 L/min
Trial: 31284680
Drug: Aerosol with
RxNorm normalized name: AEROSOL WITH ADAPTER (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol with active heated humidification at 50 L/min
Trial: 31284680
Drug: Aerosol with
RxNorm normalized name: AEROSOL WITH ADAPTER (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol with unheated oxygen at 10 L/min
Trial: 31284680
Drug: Aerosol with
RxNorm normalized name: AEROSOL WITH ADAPTER (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol with unheated oxygen at 30 L/min
Trial: 31284680
Drug: Aerosol with
RxNorm normalized name: AEROSOL WITH ADAPTER (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol with unheated oxygen at 50 L/min
Trial: 31285871
Drug: Hyperthermic intrapleural
RxNorm normalized name: INTRAPLEURAL MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermic intrapleural chemotherapy (HITHOC)
Trial: 31286197
Drug: Infrapopliteal drug-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrapopliteal drug-coated balloon angioplasty with the ELUTAX SV DCB
Trial: 31288365
Drug: Intravenous indocyanine
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous indocyanine green (5 mg/kg) 24 hours before metastasectomy
Trial: 31289029
Drug: Autologous T
RxNorm normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous T cells engineered to express an affinity-enhanced T-cell receptor (TCR) recognizing NY-ESO-1 and LAGE-1
Trial: 31289090
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (PN) during the first 7 postnatal days
Trial: 31290084
Drug: Multimodal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesia protocol (paracetamol, oxycodone, methoxyflurane)
Trial: 31291010
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine intent
Trial: 31291010
Drug: Provider recommendation
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provider recommendation for the HPV vaccine
Trial: 31291010
Drug: Positive general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive general attitude toward vaccines
Trial: 31291010
Drug: Vaccine intent
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine intent
Trial: 31291057
Drug: Early antiretroviral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antiretroviral therapy (E-ART); provided to 105 FSWs; retention at end of study: 59.0% (62/105); mean duration of follow-up: 13.4 (±7.9) months; self-reported adherence over 90%.
Trial: 31291801
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clinical and device diagnostic parameters.
Trial: 31291985
Drug: Selinexor combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor combined with high-dose cytarabine (HiDAC) and mitoxantrone (Mito)
Trial: 31292901
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) treatment for 14 days
Trial: 31294762
Drug: Pembrolizumab therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab therapy (200 mg every 21 days for 8 cycles, with provision to continue to 16 cycles)
Trial: 31294762
Drug: Pembrolizumab therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab therapy
Trial: 31296225
Drug: TyG index
RxNorm normalized name: Tygacil
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TyG index (calculated using Ln(fasting triglycerides (mg/dl) × fasting blood glucose (mg/dl)/2))
Trial: 31296423
Drug: Lenalidomide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (20 mg) plus obinutuzumab (1000 mg) as induction therapy for six 28-day cycles.
Trial: 31296423
Drug: Lenalidomide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (10 mg) plus obinutuzumab (1000 mg) for 1-year maintenance (12 28-day cycles; days 2-22) and obinutuzumab (1000 mg) for 1-year maintenance (six 56-day cycles; day 1).
Trial: 31296423
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with lenalidomide plus obinutuzumab.
Trial: 31296923
Drug: Post-operative CEA
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative CEA ≤ 2.35 ng/mL
Trial: 31296923
Drug: Post-operative CEA
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative CEA > 2.35 ng/mL
Trial: 31296923
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of oxaliplatin to adjuvant treatment
Trial: 31297046
Drug: Hypnotic Suggestion
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic Suggestion
Trial: 31297636
Drug: PF-04136309 (CCR2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04136309 (CCR2 inhibitor) plus nab-paclitaxel (125 mg/m2) and gemcitabine
Trial: 31297647
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy (HT) with aromatase inhibitors
Trial: 31298497
Drug: Feminizing hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Feminizing hormone therapy (E2 valerate and cyproterone acetate) prescribed at baseline until week 5, and then from week 8 until the end of study.
Trial: 31298497
Drug: Daily pre-exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine initiated at week 3 and continued without interruption.
Trial: 31299005
Drug: M6620 (ATR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M6620 (ATR inhibitor) and cisplatin
Trial: 31299007
Drug: Serial measurement
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial measurement of optic nerve sheath diameter (ONSD) during therapy for DKA.
Trial: 31299074
Drug: efavirenz-based ART
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: efavirenz-based ART (600 mg daily)
Trial: 31299074
Drug: nevirapine-based ART
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nevirapine-based ART (200 mg twice daily)
Trial: 31299650
Drug: Clazosentan administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clazosentan administration
Trial: 31299972
Drug: Chronic kidney
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic kidney disease (CKD) diagnosed with eGFR < 60 mL/min/1.73m²
Trial: 31300344
Drug: MGN1703 (TLR9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGN1703 (TLR9 agonist) for 24 weeks
Trial: 31301962
Drug: Ramucirumab 8
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab 8 mg/kg + Pembrolizumab 200 mg
Trial: 31301962
Drug: Ramucirumab 10
RxNorm normalized name: ramucirumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab 10 mg/kg + Pembrolizumab 200 mg
Trial: 31302344
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (CTx) with TS-1 (35 mg/m²) for two 21-day courses followed by chemoradiotherapy (CCRT)
Trial: 31303280
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement containing salmon's milt extract, 1 capsule per day for the first 4 weeks, then 1 capsule in the morning and 1 capsule in the evening for the remaining 8 weeks
Trial: 31303280
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement containing salmon's milt extract
Trial: 31303643
Drug: CFI-400945 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFI-400945 at 64 mg/day
Trial: 31303643
Drug: CFI-400945 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFI-400945 at 96 mg/day
Trial: 31303643
Drug: CFI-400945 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFI-400945 at 72 mg/day
Trial: 31303643
Drug: CFI-400945 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFI-400945 at 3 to 96 mg/day
Trial: 31306555
Drug: Daprodustat 4
RxNorm normalized name: daprodustat 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daprodustat 4 mg once daily for 4 weeks, with dose adjustments thereafter
Trial: 31306621
Drug: OAC ±
RxNorm normalized name: Oral Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC ± AP therapy
Trial: 31306621
Drug: AP therapy
RxNorm normalized name: AP-101
DrugBank: AP-101 (DB17947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP therapy
Trial: 31306621
Drug: Dual AP
RxNorm normalized name: AP-101
DrugBank: AP-101 (DB17947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual AP therapy
Trial: 31306621
Drug: OAC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC with or without AP therapy
Trial: 31307216
Drug: Maternal DENV
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal DENV neutralizing antibodies
Trial: 31307216
Drug: DENV-4 neutralizing
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DENV-4 neutralizing antibody
Trial: 31307482
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficient (<50 nmol/L)
Trial: 31307482
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D insufficient (50-75 nmol/L)
Trial: 31307482
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D replete (>75 nmol/L)
Trial: 31309541
Drug: Oral CHOP-like
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CHOP-like chemotherapy
Trial: 31310310
Drug: rhPTH(1-84) therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhPTH(1-84) therapy for 8 years
Trial: 31311898
Drug: Polypharmacy (defined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (defined as the use of 5 or more medications at one time)
Trial: 31311898
Drug: Drug-drug interactions
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-drug interactions (DDIs) determined using the Lexicomp Online drug interaction screening tool
Trial: 31311898
Drug: Potentially inappropriate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially inappropriate medications defined based on the 2015 update of the Beers Criteria
Trial: 31312030
Drug: Binimetinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binimetinib and capecitabine (DL3 dose level)
Trial: 31312030
Drug: Binimetinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binimetinib and capecitabine (DL3 dose level) in patients with RAS/RAF/MEK/ERK pathway mutations
Trial: 31312536
Drug: Nivolumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab monotherapy (NIVO)
Trial: 31312536
Drug: Ipilimumab monotherapy
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab monotherapy (IPI)
Trial: 31316378
Drug: Four off-label
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four off-label metabolically targeted medicines
Trial: 31316785
Drug: Single-dose fecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose fecal microbiota transplant (FMT)
Trial: 31316786
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for diverticular disease
Trial: 31317619
Drug: Opioid prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid prescription at discharge
Trial: 31318125
Drug: Chemotherapy (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (20 patients, 51%)
Trial: 31319038
Drug: LPS +
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS + ATP + P2X7 selective inhibitor
Trial: 31319809
Drug: Functional autonomy
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional autonomy level change as assessed by the instrumental abilities of daily living (IADL) score
Trial: 31319994
Drug: Afatinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (50 mg once daily) plus Ruxolitinib (25 mg twice daily)
Trial: 31320352
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg every 21 days for 6 weeks after the final dose of BCG)
Trial: 31320352
Drug: Pembrolizumab and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab and intravesicular BCG therapy